MADISON, N.J., Oct. 11 /PRNewswire-FirstCall/ -- Wyeth announced today that in the case of Jennie Nelson v. Wyeth, the Philadelphia Court of Common Pleas has granted Wyeth's motion for a mistrial, which was unopposed by plaintiffs.
The trial began on September 13, 2006 before The Honorable Norman Ackerman. The jury reached a verdict in favor of the plaintiff in the first, or damages, phase of this bifurcated (two phase) trial on October 4, determining that plaintiffs were injured in the amount of $1.5 million. The jury would have moved on to the second phase of the trial to determine if Wyeth is liable for those damages. The mistrial overturns the verdict in the first phase.
The plaintiff alleged that she developed breast cancer from the use of PREMPRO(TM) (conjugated estrogens/medroxyprogesterone acetate tablets), a product marketed by Wyeth.
About Wyeth
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third- party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
WyethCONTACT: Media: Christopher Garland, +1-973-660-5181, or Douglas Petkus,+1-973-660-5218; or Investors: Justin Victoria, +1-973-660-5340, all ofWyeth
Web site: http://www.wyeth.com/
